Q3 2016 EPS Estimates for Astrazeneca PLC Decreased by Analyst (AZN)
Astrazeneca PLC (NYSE:AZN) – Stock analysts at Leerink Swann dropped their Q3 2016 earnings estimates for shares of Astrazeneca PLC in a note issued to investors on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will post earnings of $0.47 per share for the quarter, down from their prior forecast of $0.56. Leerink Swann currently has a “Hold” rating and a $35.00 price target on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2018 earnings at $2.06 EPS.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. During the same period in the previous year, the company posted $1.21 earnings per share. The firm’s revenue was down 4.0% on a year-over-year basis.
A number of other equities research analysts also recently issued reports on AZN. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a research report on Tuesday, June 14th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research report on Saturday, June 25th. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, June 27th. Argus initiated coverage on Astrazeneca PLC in a research report on Tuesday, July 12th. They set a “hold” rating on the stock. Finally, Bank of America Corp. restated a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a research report on Monday, July 18th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $37.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/q3-2016-eps-estimates-for-astrazeneca-plc-decreased-by-analyst-azn.html
Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Monday. The company has a market capitalization of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75. The company’s 50 day moving average price is $33.23 and its 200 day moving average price is $30.79. Astrazeneca PLC has a 52-week low of $26.97 and a 52-week high of $35.04.
The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
Several hedge funds have recently bought and sold shares of AZN. Forester Capital Management LTD boosted its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the last quarter. First Interstate Bank boosted its stake in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares during the last quarter. Synovus Financial Corp boosted its stake in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. Fifth Third Bancorp boosted its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares during the last quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.